NCT03425110 is a clinical trial of Modified Ketogenic Diet in Epilepsy, sponsored by Birmingham and Solihull Mental Health NHS Foundation Trust.

Who is sponsoring NCT03425110?

NCT03425110 is sponsored by Birmingham and Solihull Mental Health NHS Foundation Trust.

What drugs are being tested in NCT03425110?

Interventions in NCT03425110: Modified Ketogenic Diet.

Is NCT03425110 still recruiting?

NCT03425110 is currently status unknown. Last updated 9 February 2018.

Last reviewed 2018-02-09 · How we verify

NCT03425110

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Modified Ketogenic Diet for the Treatment of Pharmacoresistant Epilepsy in Adults

Status unknown Last updated 9 February 2018

What this trial tests

trial testing Modified Ketogenic Diet in Epilepsy in 30 participants. Status unknown.

Timeline

21 July 2015

Primary endpoint
30 June 2018

1 September 2018

Quick facts

Lead sponsor	Birmingham and Solihull Mental Health NHS Foundation Trust
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	30
Start date	21 July 2015
Primary completion	30 June 2018
Estimated completion	1 September 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

Modified Ketogenic Diet

Conditions studied

Epilepsy — all drugs for Epilepsy →

Sponsor

Birmingham and Solihull Mental Health NHS Foundation Trust

Who can join

Adults 18 to 100, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Modified Ketogenic Diet for the Treatment of Pharmacoresistant Epilepsy in Adults: an Observational Cohort Study

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Modified Ketogenic Diet

Trials testing the same drug.

NCT06454162 — Effect of Adding Modified Ketogenic Diet to Exercise Program in Treating Obese Patient With Multiple Sclerosis: A Random · NA · not yet recruiting

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03425110 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Birmingham and Solihull Mental Health NHS Foundation Trust
Last refreshed: 9 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03425110.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing